Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double blind study of BoNT/A-DP for glabellar lines
2015-002164-16Phase 3Completed
- Sponsor
- Croma-Pharma
- Start
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in glabellar furrowing (2 arms), sponsored by Croma-Pharma. Primary endpoint: Primary responder rate at week 4. Started Nov 2015; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on 2015-002164-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002164-16.